Profile data is unavailable for this security.
About the company
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.
- Revenue in USD (TTM)0.00
- Net income in USD-61.28m
- Incorporated2015
- Employees82.00
- LocationNextCure Inc9000 Virginia Manor Rd Ste 200BELTSVILLE 20705-4214United StatesUSA
- Phone+1 (240) 399-4900
- Fax+1 (302) 655-5049
- Websitehttps://www.nextcure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Provectus Biopharmaceuticals Inc | 683.90k | -2.79m | 37.75m | 4.00 | -- | -- | -- | 55.20 | -0.0067 | -0.0067 | 0.0016 | -0.0179 | 0.5379 | -- | 613.36 | 170,975.00 | -219.43 | -276.33 | -- | -- | -- | -- | -407.97 | -1,667.76 | -- | -9.75 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -21.60m | 38.18m | 29.00 | -- | 3.19 | -- | -- | -1.33 | -1.33 | 0.00 | 0.4682 | 0.00 | -- | -- | 0.00 | -115.33 | -- | -170.44 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0396 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 38.38m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| NextCure Inc | 0.00 | -61.28m | 40.01m | 82.00 | -- | 0.4682 | -- | -- | -2.20 | -2.20 | 0.00 | 3.05 | 0.00 | -- | -- | 0.00 | -47.88 | -22.59 | -51.64 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| OncoCyte Corp | 1.02m | -36.80m | 40.11m | 43.00 | -- | 1.77 | -- | 39.20 | -4.26 | -4.26 | 0.1087 | 1.70 | 0.0126 | -- | 1.14 | 23,790.70 | -44.55 | -35.11 | -49.04 | -39.71 | 8.11 | -- | -3,532.75 | -2,373.36 | -- | -154.75 | 0.0212 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Singular Genomics Systems Inc | 2.72m | -91.89m | 40.48m | 255.00 | -- | 0.2935 | -- | 14.87 | -37.37 | -37.37 | 1.11 | 55.27 | 0.0108 | 0.2867 | 11.53 | 10,674.51 | -36.46 | -- | -38.85 | -- | -41.11 | -- | -3,375.72 | -- | 8.04 | -- | 0.0696 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -24.41m | 40.57m | 14.00 | -- | -- | -- | -- | -0.2843 | -0.2843 | 0.00 | 0.7193 | 0.00 | -- | -- | 0.00 | -68.77 | -218.20 | -118.93 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -40.69m | 40.64m | 26.00 | -- | 0.4415 | -- | -- | -3.19 | -3.19 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -41.35 | -37.02 | -43.70 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Carisma Therapeutics Inc | 20.71m | -72.50m | 40.74m | 107.00 | -- | 113.16 | -- | 1.97 | -1.78 | -1.78 | 0.5075 | 0.0087 | 0.2153 | -- | -- | 193,551.40 | -75.38 | -30.87 | -91.33 | -34.47 | -- | -- | -350.08 | -255.66 | -- | -- | 0.8322 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| HST Global Inc | 0.00 | -123.45k | 41.56m | 1.00 | -- | -- | -- | -- | -0.0209 | -0.0209 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -3,300.80 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -27.31 | 5.81 | -- | -- | -- | -0.7858 | -- | -- | -- |
| FibroGen Inc | 173.82m | -168.32m | 41.77m | 486.00 | -- | -- | -- | 0.2403 | -1.71 | -1.71 | 1.76 | -2.31 | 0.4301 | 1.22 | 44.10 | 357,644.00 | -42.40 | -30.62 | -89.79 | -42.31 | 76.65 | 93.52 | -98.60 | -119.08 | 1.24 | -12.47 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Kezar Life Sciences Inc | 7.00m | -98.57m | 42.51m | 58.00 | -- | 0.2818 | -- | 6.07 | -1.35 | -1.35 | 0.0962 | 2.07 | 0.0316 | -- | -- | 120,689.70 | -44.47 | -32.54 | -47.84 | -34.09 | -- | -- | -1,408.11 | -4,308.11 | -- | -- | 0.0634 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| DURECT Corp | 8.41m | -15.80m | 42.52m | 47.00 | -- | 8.44 | -- | 5.06 | -0.5283 | -0.5283 | 0.2842 | 0.1623 | 0.2143 | 0.682 | 7.26 | 145,017.20 | -40.25 | -37.34 | -208.53 | -53.44 | 80.80 | 91.83 | -187.84 | -139.11 | 0.797 | -38.83 | 0.7135 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Passage Bio Inc | 0.00 | -76.57m | 43.24m | 58.00 | -- | 0.4774 | -- | -- | -1.36 | -1.36 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -47.99 | -48.56 | -53.39 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -35.51m | 43.35m | 15.00 | -- | -- | -- | -- | -1.30 | -1.30 | 0.00 | -0.2026 | 0.00 | -- | -- | 0.00 | -356.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to NextCure Inc's reporting currency: US Dollar USD
31.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Logos Global Management LPas of 30 Jun 2024 | 2.50m | 8.94% |
| Affinity Asset Advisors LLCas of 30 Jun 2024 | 1.69m | 6.03% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 987.32k | 3.53% |
| Cable Car Capital LLCas of 30 Jun 2024 | 615.88k | 2.20% |
| Tang Capital Management LLCas of 30 Jun 2024 | 602.99k | 2.16% |
| Long Focus Capital Management LLCas of 30 Jun 2024 | 556.11k | 1.99% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 497.62k | 1.78% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 488.44k | 1.75% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 462.14k | 1.65% |
| Millennium Management LLCas of 30 Jun 2024 | 458.34k | 1.64% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
